ADU-1805

N/A

Report date: 2024/11/15 14:54:53

Base Information

Drug NameADU-1805
Drug Alias NameADU-1805
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionSignal-regulatory protein alpha inhibitors
TargetsSignal-regulatory protein alpha
Therapy Area/IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesSpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAduro Biotech Inc
China Registration ClassN/A

Develop Information

Active CompaniesSairopa BVExelixis Inc
Inactive CompaniesAduro Biotech Inc
Active IndicationsSolid tumoursEndometrial NeoplasmsCarcinoma, Non-Small-Cell Lung +[5] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A